Stay updated on ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has updated its version from v2.14.4 to v2.15.0, indicating a revision in the content. The phrase 'Here’s how you know' has been removed and replaced with a similar phrase.SummaryDifference1.0%
- Check20 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 3, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.7%
- Check27 days agoNo Change Detected
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check77 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting NLM-NCBI services and products, along with a contact for assistance. Additionally, a date has been updated from October 24, 2024, to February 3, 2025.SummaryDifference7%
- Check85 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check99 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
Stay in the know with updates to ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.